|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS: | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory, net | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease - right of use asset | ||||||||||||||||||||
| Investment in NexGelRx | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable - related party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts payable - related party | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Current portion of note payable | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Partnership accrued advance | ||||||||||||||||||||
| Warrant liability and contingent consideration liability | ||||||||||||||||||||
| Current portion of finance lease liability | ||||||||||||||||||||
| Current portion of operating lease liability | ||||||||||||||||||||
| Derivative liability, at fair value | ||||||||||||||||||||
| Contingent consideration liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Financing lease liability, net of current portion | ||||||||||||||||||||
| Convertible notes payable | ||||||||||||||||||||
| Convertible notes payable, net of debt discount | ||||||||||||||||||||
| Notes payable, net of current portion | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ Equity | ||||||||||||||||||||
| Common stock, par value $0.001 per share, 25,000,000 shares authorized; 9,700,022 and 8,475,693 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total NexGel stockholders’ equity | ||||||||||||||||||||
| Non-controlling interest in joint venture | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...